As per NAVADHI Market Research, the global pharmaceutical industry [2] will we worth USD 1.57 trillion by 2023.
GlaxoSmithKline (GSK) is a global pharmaceutical and consumer health products company and is headquartered in Brentford, the UK. The company operates in more than 100 countries and has a strong presence in US, Europe and Asia-Pacific.
GSK is looking forward to expanding its product portfolio and is investing heavily on Research and development for the same. The company has 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
GlaxoSmithKline reported revenue of USD 40.992 billion for the FY 2018 which saw an increase of 4.46% compared to FY 2017. Consumer healthcare division had second largest revenue share with 24.85% revenue share. This division saw an increase of 1.09% compared to FY 2017 revenue.
GlaxoSmithKline registered highest revenue from respiratory (Seretide/ Advair, Ellipta Products (Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta, Relvar/ Breo Ellipta, Trelegy Ellipta), Nucala/ Mepolizumab, Avamys/ Veramyst, Flixotide/ Flovent, Ventolin and Other) at USD 9.214 billion which accounted for 40.12% of its total pharmaceuticals sales in FY 2018.
Spanning over 29 pages and 10 exhibits, “GlaxoSmithKline Plc - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
GlaxoSmithKline Plc
*If Applicable.